279 related articles for article (PubMed ID: 32114890)
1. Socioeconomic Factors, Secondary Prevention Medication, and Long-Term Survival After Coronary Artery Bypass Grafting: A Population-Based Cohort Study From the SWEDEHEART Registry.
Nielsen SJ; Karlsson M; Björklund E; Martinsson A; Hansson EC; Malm CJ; Pivodic A; Jeppsson A
J Am Heart Assoc; 2020 Mar; 9(5):e015491. PubMed ID: 32114890
[TBL] [Abstract][Full Text] [Related]
2. Secondary prevention medications after coronary artery bypass grafting and long-term survival: a population-based longitudinal study from the SWEDEHEART registry.
Björklund E; Nielsen SJ; Hansson EC; Karlsson M; Wallinder A; Martinsson A; Tygesen H; Romlin BS; Malm CJ; Pivodic A; Jeppsson A
Eur Heart J; 2020 May; 41(17):1653-1661. PubMed ID: 31638654
[TBL] [Abstract][Full Text] [Related]
3. Statins for secondary prevention and major adverse events after coronary artery bypass grafting.
Pan E; Nielsen SJ; Mennander A; Björklund E; Martinsson A; Lindgren M; Hansson EC; Pivodic A; Jeppsson A
J Thorac Cardiovasc Surg; 2022 Dec; 164(6):1875-1886.e4. PubMed ID: 34893327
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of preventive cardiovascular pharmacotherapy after coronary artery bypass graft surgery.
Barry AR; Koshman SL; Norris CM; Ross DB; Pearson GJ
Pharmacotherapy; 2014 May; 34(5):464-72. PubMed ID: 24877186
[TBL] [Abstract][Full Text] [Related]
5. Social Factors, Sex, and Mortality Risk After Coronary Artery Bypass Grafting: A Population-Based Cohort Study.
Nielsen S; Giang KW; Wallinder A; Rosengren A; Pivodic A; Jeppsson A; Karlsson M
J Am Heart Assoc; 2019 Mar; 8(6):e011490. PubMed ID: 30852925
[TBL] [Abstract][Full Text] [Related]
6. Utilization of Evidence-Based Secondary Prevention Medications at the Time of Discharge in Patients with Acute Coronary Syndrome (ACS) in Qatar.
El-Hajj MS; Saad A; Al-Suwaidi J; Al-Marridi WZ; Elkhalifa DH; Mohamed AA; Mahfoud ZR
Curr Vasc Pharmacol; 2016; 14(4):394-403. PubMed ID: 26916397
[TBL] [Abstract][Full Text] [Related]
7. Education of Migrant and Nonmigrant Patients Is Associated With Initiation and Discontinuation of Preventive Medications for Acute Coronary Syndrome.
Frederiksen HW; Zwisler AD; Johnsen SP; Öztürk B; Lindhardt T; Norredam M
J Am Heart Assoc; 2019 Jun; 8(11):e009528. PubMed ID: 31140348
[TBL] [Abstract][Full Text] [Related]
8. Rationale and design of a randomized cluster trial to improve guideline-adherence of secondary preventive drugs prescription after coronary artery bypass grafting in China: Measurement and Improvement Studies of Surgical Coronary Revascularization: Secondary Prevention (MISSION-1) Study.
Rao C; Du J; Li X; Li J; Zhang H; Zhao Y; Hu S; Jiang L; Zheng Z;
Am Heart J; 2016 Aug; 178():9-18. PubMed ID: 27502847
[TBL] [Abstract][Full Text] [Related]
9. New-Onset Atrial Fibrillation After Coronary Artery Bypass Grafting and Long-Term Outcome: A Population-Based Nationwide Study From the SWEDEHEART Registry.
Taha A; Nielsen SJ; Bergfeldt L; Ahlsson A; Friberg L; Björck S; Franzén S; Jeppsson A
J Am Heart Assoc; 2021 Jan; 10(1):e017966. PubMed ID: 33251914
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal persistence with secondary prevention therapies relative to patient risk after myocardial infarction.
Shore S; Jones PG; Maddox TM; Bradley SM; Stolker JM; Arnold SV; Parashar S; Peterson P; Bhatt DL; Spertus J; Ho PM
Heart; 2015 May; 101(10):800-7. PubMed ID: 25801001
[TBL] [Abstract][Full Text] [Related]
11. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey.
Yusuf S; Islam S; Chow CK; Rangarajan S; Dagenais G; Diaz R; Gupta R; Kelishadi R; Iqbal R; Avezum A; Kruger A; Kutty R; Lanas F; Lisheng L; Wei L; Lopez-Jaramillo P; Oguz A; Rahman O; Swidan H; Yusoff K; Zatonski W; Rosengren A; Teo KK;
Lancet; 2011 Oct; 378(9798):1231-43. PubMed ID: 21872920
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular Medication Use and Long-Term Outcomes of First Nations and Non-First Nations Patients Following Diagnostic Angiography: A Retrospective Cohort Study.
Dahl L; Schultz A; McGibbon E; Brownlie J; Cook C; Elbarouni B; Katz A; Nguyen T; Sawatzky JA; Sinclaire M; Throndson K; Prior HJ; Fransoo R
J Am Heart Assoc; 2019 Aug; 8(16):e012040. PubMed ID: 31405352
[TBL] [Abstract][Full Text] [Related]
13. Should all patients be treated with an angiotensin-converting enzyme inhibitor after coronary artery bypass graft surgery? The impact of angiotensin-converting enzyme inhibitors, statins, and β-blockers after coronary artery bypass graft surgery.
Kalavrouziotis D; Buth KJ; Cox JL; Baskett RJ
Am Heart J; 2011 Nov; 162(5):836-43. PubMed ID: 22093199
[TBL] [Abstract][Full Text] [Related]
14. Use of cardiovascular medical therapy among patients undergoing coronary artery bypass graft surgery: results from the ROSETTA-CABG registry.
Okrainec K; Pilote L; Platt R; Eisenberg MJ
Can J Cardiol; 2006 Aug; 22(10):841-7. PubMed ID: 16957801
[TBL] [Abstract][Full Text] [Related]
15. Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery.
Goyal A; Alexander JH; Hafley GE; Graham SH; Mehta RH; Mack MJ; Wolf RK; Cohn LH; Kouchoukos NT; Harrington RA; Gennevois D; Gibson CM; Califf RM; Ferguson TB; Peterson ED;
Ann Thorac Surg; 2007 Mar; 83(3):993-1001. PubMed ID: 17307447
[TBL] [Abstract][Full Text] [Related]
16. Optimal secondary prevention medication use in acute myocardial infarction patients with nonobstructive coronary artery disease is modified by management strategy: insights from the TRIUMPH Registry.
Pitts R; Daugherty SL; Tang F; Jones P; Ho PM; Tsai TT; Spertus J; Maddox TM
Clin Cardiol; 2017 Jun; 40(6):347-355. PubMed ID: 28387960
[TBL] [Abstract][Full Text] [Related]
17. Use of perioperative cardiac medical therapy among patients undergoing coronary artery bypass graft surgery.
Filion KB; Pilote L; Rahme E; Eisenberg MJ
J Card Surg; 2008; 23(3):209-15. PubMed ID: 18435634
[TBL] [Abstract][Full Text] [Related]
18. Renin-angiotensin system inhibition and outcome after coronary artery bypass grafting: A population-based study from the SWEDEHEART registry.
Martinsson A; Nielsen SJ; Björklund E; Pivodic A; Malm CJ; Hansson EC; Jeppsson A
Int J Cardiol; 2021 May; 331():40-45. PubMed ID: 33359277
[TBL] [Abstract][Full Text] [Related]
19. Statin treatment equalizes long-term survival between patients with single and bilateral internal thoracic artery grafts.
Carrier M; Cossette M; Pellerin M; Hébert Y; Bouchard D; Cartier R; Demers P; Jeanmart H; Pagé P; Perrault LP
Ann Thorac Surg; 2009 Sep; 88(3):789-95; discussion 795. PubMed ID: 19699899
[TBL] [Abstract][Full Text] [Related]
20. The UK National Health Service: delivering equitable treatment across the spectrum of coronary disease.
Hawkins NM; Scholes S; Bajekal M; Love H; O'Flaherty M; Raine R; Capewell S
Circ Cardiovasc Qual Outcomes; 2013 Mar; 6(2):208-16. PubMed ID: 23481523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
